Management of dyslipidaemia - Evidence and practical recommendations

Australian Family Physician

Volumn 37, Issue 7, 2008, Pages 521-527

  Nestel, Paul J ^a   O'Brien, Richard ^b   Nelson, Mark ^c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HUMAN; LIFESTYLE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; LIFE STYLE; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 50549091935     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-61.
2. New Zealand Risk Calculator. Available at www.racp.edu.au/bp/resources/ EBM_cardio.pdf [Accessed October 2007].
3. Available at www.absoluterisk.com/ [Accessed October 2007].
4. Wang Z, We H. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people? Med J Aust 2005;182:66-9.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position Statement on Lipid Management 2005. Heart Lung Circ 2005;14:275-91.
6. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
7. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. Available at www.idf.org/webdata/docs/ metsyndrome_final.pdf [Accessed August 2007].
8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
9. LaRosa J, Grundy S, Waters D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005;352:1425-35.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study: randomised placebo-controlled trial of cholesterol-lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360:7-22.
11. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
12. Norman PE, Eikelboom J, Hankey GJ. Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J of Aust 2004;181:150-4.
13. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508.
14. Olsson A, Pear JS, Mckellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.
15. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
16. Packard C. High density lipoprotein: guardian of the vascular system? Int J Clin Pract 2002;56:761-71.
17. Commonwealth Department of Health and Ageing. Smoking cessation interventions: Review of evidence and implications for best practice in health care settings. August 2001.
18. Camargo CA Jr., Stampfer MJ, Glynn RJ, et al. Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation 1997;95:577-80.
19. Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: Pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2007; Aug 16.
20. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20.
21. Simons LA, Sullivan DR. Lipid-modifying drags. Med J Aust 2005;182:286-9.
22. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol 1992;70:733-7.